Ebronucimab vs RBD7022
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
RBD7022
Developed by Suzhou Ribo Life Science
NCT05912296 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0 (SAD up to Day 180; MAD up to Day 208): Using PCSK9 levels as a marker of target engagement, in patients with and without statin background therapy, RBD7022 produced a maximal reduction of up to 75%, with that level of suppression maintained at 6 months of follow-up.
Result source: NCT05912296
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ebronucimab | RBD7022 |
|---|---|---|
| LDL-C, % change | —Not posted · NCT05260411 | —Not reported |
| Non-HDL-C, % change | —Not posted · NCT05260411 | —Not reported |
| ApoB, % change | —Not posted · NCT05260411 | —Not reported |
| Lp(a), % change | —Not posted · NCT05260411 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05260411 | —Not reported |
LDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- RBD7022
- —Not reported
Non-HDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- RBD7022
- —Not reported
ApoB, % change
- Ebronucimab
- —Not posted · NCT05260411
- RBD7022
- —Not reported
Lp(a), % change
- Ebronucimab
- —Not posted · NCT05260411
- RBD7022
- —Not reported
3-point MACE (% with event)
- Ebronucimab
- —Not posted · NCT05260411
- RBD7022
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
RBD7022: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ebronucimab
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · RBD7022's landscape